Abstract
This review article describes the development of in vivo active antagonists for the glycine binding site of the NMethyl- D-Aspartate (NMDA) receptor. There were several difficulties in identifying a class of antagonists with in vivo efficacy and only a few compounds succeeded in emerging with activity in vivo. A series of tricyclic quinoxalinediones was highly potent glycine antagonists in vitro and the derivatives having a zwitterionic moiety including SM-18400 indeed showed in vivo activity. Similarly, tricyclic indole-2-carboxylic acids having a zwitterionic moiety such as SM- 31900 were also active in vivo. In fact, SM-18400 and SM-31900 exhibited efficacy in several animal stroke models using intravenous infusion protocols. The practical syntheses of SM-18400 and SM-31900 as well as the novel synthesis of moderately active glycine antagonists, tricyclic azakynurenic acids, were also developed.
Keywords: N-Methyl-D-Aspartate, NMDA-glycine antagonist, SM-18400, SM-31900, tricyclic quinoxalinedione, tricyclic indole-2-carboxylic acid
Current Topics in Medicinal Chemistry
Title: Tricyclic Quinoxalinediones, Aza-kynurenic Acids, and Indole-2- Carboxylic Acids as In Vivo Active NMDA-Glycine Antagonists
Volume: 6 Issue: 7
Author(s): Ryu Nagata, Seiji Katayama, Ken-ichi Ohtani, Hiroyasu Tanaka and Kozo Shimago
Affiliation:
Keywords: N-Methyl-D-Aspartate, NMDA-glycine antagonist, SM-18400, SM-31900, tricyclic quinoxalinedione, tricyclic indole-2-carboxylic acid
Abstract: This review article describes the development of in vivo active antagonists for the glycine binding site of the NMethyl- D-Aspartate (NMDA) receptor. There were several difficulties in identifying a class of antagonists with in vivo efficacy and only a few compounds succeeded in emerging with activity in vivo. A series of tricyclic quinoxalinediones was highly potent glycine antagonists in vitro and the derivatives having a zwitterionic moiety including SM-18400 indeed showed in vivo activity. Similarly, tricyclic indole-2-carboxylic acids having a zwitterionic moiety such as SM- 31900 were also active in vivo. In fact, SM-18400 and SM-31900 exhibited efficacy in several animal stroke models using intravenous infusion protocols. The practical syntheses of SM-18400 and SM-31900 as well as the novel synthesis of moderately active glycine antagonists, tricyclic azakynurenic acids, were also developed.
Export Options
About this article
Cite this article as:
Nagata Ryu, Katayama Seiji, Ohtani Ken-ichi, Tanaka Hiroyasu and Shimago Kozo, Tricyclic Quinoxalinediones, Aza-kynurenic Acids, and Indole-2- Carboxylic Acids as In Vivo Active NMDA-Glycine Antagonists, Current Topics in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/156802606776894500
DOI https://dx.doi.org/10.2174/156802606776894500 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model
Current Drug Delivery Using Simulations to Explore the Characteristics of CT Perfusion Calculations in the Assessment of Stroke
Current Medical Imaging Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416
Current Vascular Pharmacology Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Treating Neonatal Brain Injury - Promise and Inherent Research Challenges
Recent Patents on Inflammation & Allergy Drug Discovery New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications
Cardiovascular & Hematological Disorders-Drug Targets Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Retinal Imaging: A New Tool for Studying Underlying Liability to Cardiovascular Disease in Schizophrenia
Current Psychiatry Reviews Contemporary Management of Deep Vein Thrombosis, Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Engineering Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Efficacy and Cardiovascular Safety of Meglitinides
Current Drug Safety Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry